Regenerative medicine using mesenchymal stem cells for the purposes of tissue repair has garnered considerable public attention due to the potential of returning tissues and organs to a normal, healthy state after injury or damage has occurred. To achieve this, progenitor cells such as pericytes and bone marrow-derived mesenchymal stem cells can be delivered exogenously, mobilised and recruited from within the body or transplanted in the form organs and tissues grown in the laboratory from stem cells. In this review, we summarise the recent evidence supporting the use of endogenously mobilised stem cell populations to enhance tissue repair along with the use of mesenchymal stem cells and pericytes in the development of engineered tissues. Finally, we conclude with an overview of currently available therapeutic options to manipulate endogenous stem cells to promote tissue repair.

Prostate cancer is an androgen receptor (AR)-dependent malignancy at initiation and progression, therefore hormone therapy is the primary line of systemic treatment. Despite initial disease regression, tumours inevitably recur and progress to an advanced castration-resistant state a major feature of which is metastasis to the bone. Up-regulation of AR cofactors and chaperones that overcome low hormone conditions to maintain basal AR activity has been postulated as a mechanism of therapy relapse.p23, an essential component of the apo-AR complex, acts also after ligand binding to increase AR transcriptional activity and target gene expression, partly by increasing chromatin-loaded holo-receptor-complexes. Immunohistochemical studies have demonstrated increased p23 expression in advanced prostate cancer. Here, we further characterise p23 roles in AR signalling and show that it modulates cytosolic AR levels in the absence of hormone, confirming a chaperoning function in the aporeceptor complex and suggesting p23 upregulates AR signalling at multiple stages. Moreover, p23 protein levels significantly increased upon treatment with not only androgen but also clinically relevant anti-androgens. This was in contrast to the HSP90 inhibitor 17-AAG, which did not modulate expression of the cochaperone – important given the HSP90-independent roles we and others have previously described for p23.Further, we demonstrate p23 is implicated in prostate cancer cell motility and in acquisition of invasiveness capacity through the expression of specific genes known to participate in cancer progression. This may drive metastatic processes in vivo since analysis of prostate tumour biopsies revealed that high nuclear p23 significantly correlated with shorter survival times and with development of metastases in patients with lower grade tumours. We propose that increased p23 expression may allow cells to acquire a more aggressive phenotype, contributing to disease progression, and that p23 is a plausible secondary target in combination with HSP90 inhibition as a potential therapy for advanced prostate cancer.

Accurate disease models are essential for understanding disease pathogenesis and for developing new therapeutics. As stem cells are capable of self-renewal and differentiation, they are ideally suited both for generating these models and for obtaining the large quantities of cells required for drug development and transplantation therapies. Jellyfish collagen is showing great promise as a next generation matrix enabling improved outcomes in 2D and 3D cell culture and regenerative medicine. Here, we report the potential of jellyfish collagen for culturing induced pluripotent stem cell derived cell lines (iPSCs) for modeling human diseases. Jellyfish collagen from Rhizostoma pulmo (Jellagen R) was evaluated for the growth and viability of iPSC-derived microgliallike cells (iMGL) comparing to cells cultured on rat tail collagen 1, laminin-511 and tissue culture plastic. Viability was measured using MTT, XTT, Alamar Blue and Annexin V, since this last assay has the aim of evaluating the onset of apoptosis. Cell ramification was measured using Neurotracker software and ramification measured on the InCucyte S3 TM. Cell surface receptor expression was quantified using flow cytometry. Microglia markers used for immunocytochemistry were IBA1, CD11b, TREM2, TMEM119, and P2RY12. We report that iPSC-derived microglia can be successfully cultured on Jellagen R jellyfish collagen demonstrating a more ramified cell morphology compared to cells cultured on mammalian rat tail collagen I and comparable to Laminin-511.

No abstract

No abstract